Drugs / ECa233
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT06231212 | Aug 2020 → Sep 2021 | temporomandibular joint disorder | Chulalongkorn University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ECa233 | “To determine the efficacy of Centella asiatica extract, ECa233, on alleviating pain symptoms and functional improvement of acute temporomandibular disorders (TMD).” PMID 40253389 ↗ Apr 2025 |
| Known as | Centella asiatica extract | “To determine the efficacy of Centella asiatica extract, ECa233, on alleviating pain symptoms and functional improvement of acute temporomandibular disorders (TMD).” PMID 40253389 ↗ Apr 2025 |
| Route | Oral | “The orally administered ECa233 has the potential to induce rapid, short term, dose-dependent analgesia in individuals with TMD pain.” PMID 40253389 ↗ Apr 2025 |